Karl V Clemons

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/66367/karl-v-clemons-publications-by-year.pdf
Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

41 papers	1,109 citations	20 h-index	32 g-index
42 ext. papers	1,281 ext. citations	4.6 avg, IF	4.12 L-index

#	Paper	IF	Citations
41	Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as a Model to Study Trypanosoma cruzi Infection. *Stem Cell Reports*, **2019**, 12, 1232-1241	8	15
40	The role of occupational Aspergillus exposure in the development of diseases. *Medical Mycology*, **2019**, 57, S196-S205	3.9	20
39	Aspergillus-Pseudomonas interaction, relevant to competition in airways. *Medical Mycology*, **2019**, 57, S228-S232	3.9	26
38	Molecular identification of clinical and environmental avian Aspergillus isolates. *Archives of Microbiology*, **2019**, 201, 253-257	3	14
37	Microhemorrhage-associated tissue iron enhances the risk for invasion in a mouse model of airway transplantation. *Science Translational Medicine*, **2018**, 10,	17.5	18
36	Amphotericin B concentrations in healthy mallard ducks (Anas platyrhynchos) following a single intratracheal dose of liposomal amphotericin B using an atomizer. *Medical Mycology*, **2018**, 56, 322-331	3.9	3
35	Studies of Pseudomonas aeruginosa Mutants Indicate Pyoverdine as the Central Factor in Inhibition of Aspergillus fumigatus Biofilm. *Journal of Bacteriology*, **2018**, 200,	3.5	62
34	Small Colony Variants of Pseudomonas aeruginosa Display Heterogeneity in Inhibiting Aspergillus fumigatus Biofilm. *Mycopathologia*, **2018**, 183, 263-272	2.9	13
33	Effect of Anaerobiasis or Hypoxia on Pseudomonas aeruginosa Inhibition of Aspergillus fumigatus Biofilm. *Archives of Microbiology*, **2017**, 199, 881-890	3	16
32	Are Cystic Fibrosis Aspergillus fumigatus Isolates Different? Intermicrobial Interactions with Pseudomonas. *Mycopathologia*, **2017**, 182, 315-318	2.9	10
31	Lack of Efficacy of Liposomal Amphotericin B Against Acute and Chronic Infection in Mice. *American Journal of Tropical Medicine and Hygiene*, **2017**, 97, 1141-1146	3.2	8
30	The cryptococcal antigen lateral flow assay: A point-of-care diagnostic at an opportune time. *Critical Reviews in Microbiology*, **2016**, 42, 634-42	7.8	22
29	Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2180-4	5.9	13
28	Pf4 bacteriophage produced by Pseudomonas aeruginosa inhibits Aspergillus fumigatus metabolism via iron sequestration. *Microbiology (United Kingdom)*, **2016**, 162, 1583-1594	2.9	44
27	Proteomic Analysis of Pathogenic Fungi Reveals Highly Expressed Conserved Cell Wall Proteins. *Journal of Fungi (Basel, Switzerland)*, **2016**, 2,	5.6	36
26	Biofilm Filtrates of Pseudomonas aeruginosa Strains Isolated from Cystic Fibrosis Patients Inhibit Preformed Aspergillus fumigatus Biofilms via Apoptosis. *PLoS ONE*, **2016**, 11, e0150155	3.7	36
25	Antifungal susceptibility of 175 Aspergillus isolates from various clinical and environmental sources. *Medical Mycology*, **2016**, 54, 740-756	3.9	19

24	The brain, amphotericin B, and P-glycoprotein. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1386	5.9	6
23	Analysis of the Aspergillus fumigatus Biofilm Extracellular Matrix by Solid-State Nuclear Magnetic Resonance Spectroscopy. *Eukaryotic Cell*, **2015**, 14, 1064-72		51
22	Effects of Iron Chelators on the Formation and Development of Aspergillus fumigatus Biofilm. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 6514-20	5.9	27
21	Evaluating Common Humoral Responses against Fungal Infections with Yeast Protein Microarrays. *Journal of Proteome Research*, **2015**, 14, 3924-31	5.6	7
20	Molecular epidemiology of Aspergillus collected from cystic fibrosis patients. *Journal of Cystic Fibrosis*, **2015**, 14, 474-81	4.1	41
19	Inhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium. *PLoS ONE*, **2015**, 10, e0134692	3.7	62
18	Whole glucan particles as a vaccine against systemic coccidioidomycosis. *Journal of Medical Microbiology*, **2015**, 64, 1237-1243	3.2	13
17	Monitoring of fungal loads in seabird rehabilitation centers with comparisons to natural seabird environments in northern California. *Journal of Zoo and Wildlife Medicine*, **2014**, 45, 29-40	0.9	13
16	Whole glucan particles as a vaccine against murine aspergillosis. *Journal of Medical Microbiology*, **2014**, 63, 1750-1759	3.2	23
15	Molecular screening of 246 Portuguese Aspergillus isolates among different clinical and environmental sources. *Medical Mycology*, **2014**, 52, 519-29	3.9	43
14	Application of a non-amplification-based technology to detect invasive fungal pathogens. *Diagnostic Microbiology and Infectious Disease*, **2014**, 78, 137-40	2.9	2
13	Heat-killed yeast protects diabetic ketoacidotic-steroid treated mice from pulmonary mucormycosis. *Vaccine*, **2014**, 32, 3573-6	4.1	13
12	Vitamin D and experimental invasive aspergillosis. *Medical Mycology*, **2014**, 52, 847-52	3.9	4
11	Development and validation of a quantitative real-time PCR assay for the early diagnosis of coccidioidomycosis. *Diagnostic Microbiology and Infectious Disease*, **2014**, 79, 214-21	2.9	21
10	Aspergillus fumigatus invasion increases with progressive airway ischemia. *PLoS ONE*, **2013**, 8, e77136	3.7	32
9	Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis. *Medical Mycology*, **2011**, 49, 834-47	3.9	18
8	Genomic DNA microarray comparison of gene expression patterns in Paracoccidioides brasiliensis mycelia and yeasts in vitro. *Microbiology (United Kingdom)*, **2009**, 155, 2795-2808	2.9	26
7	Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. *Medical Mycology*, **2006**, 44, 69-73	3.9	41

6	Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. *Journal of Antimicrobial Chemotherapy*, **2000**, 46, 437-42	5.1	50
5	Molecular epidemiology of the global and temporal diversity of Candida albicans. *Clinical Infectious Diseases*, **1999**, 29, 1220-5	11.6	49
4	Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea. *Journal of Clinical Microbiology*, **1999**, 37, 417-21	9.7	139
3	Epidemiological investigation of vaginal Saccharomyces cerevisiae isolates by a genotypic method. *Journal of Clinical Microbiology*, **1998**, 36, 557-62	9.7	46
2	Ubiquinone systems of Coccidioides immitis, the causative agent of coccidioidomycosis. *FEMS Microbiology Letters*, **1993**, 108, 243-5	2.9	5
1	Cryptococcosis in Experimental Animals: Lessons Learned473-488		1